Source: Medical Device News Magazine

HiFiBiO: HiFiBiO Therapeutics Announces First Patient Dosed with HFB200301 in Combination with tislelizumab in Patients with DIS Selected Advanced Solid Tumors

Liang Schweizer, PhD, Founder, CEO, and Chairperson of HiFiBiO Therapeutics, "This marks a major step toward further understanding the therapeutic activity of HFB200301 and how we can best deliver safe and effective treatment strategies for cancer patients where other therapeutic options have failed."

Read full article »
HiFiBiO's Competitors | HiFiBiO's News | HiFiBiO's Financials
Stay up-to-date with the latest news on HiFiBiO
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Liang Schweizer's photo - Chairman & CEO of HiFiBiO

Chairman & CEO

Liang Schweizer

CEO Approval Rating

88/100

Read more
Stay up-to-date with the latest news on HiFiBiO